Regeneron drug tops rivals in some vision loss cases By: CNBC.com News February 18, 2015 at 17:00 PM EST Regeneron Pharmaceuticals' top-selling eye drug, Eylea, bested Roche's Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss. Read More >> Related Stocks: Regeneron Pharmaceuticals